IL296857A - Preparations and methods for the treatment of neurological disorders - Google Patents

Preparations and methods for the treatment of neurological disorders

Info

Publication number
IL296857A
IL296857A IL296857A IL29685722A IL296857A IL 296857 A IL296857 A IL 296857A IL 296857 A IL296857 A IL 296857A IL 29685722 A IL29685722 A IL 29685722A IL 296857 A IL296857 A IL 296857A
Authority
IL
Israel
Prior art keywords
raav
subject
nucleic acid
viral vector
aav
Prior art date
Application number
IL296857A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL296857A publication Critical patent/IL296857A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL296857A 2020-04-15 2021-04-14 Preparations and methods for the treatment of neurological disorders IL296857A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010179P 2020-04-15 2020-04-15
PCT/US2021/027266 WO2021211700A1 (en) 2020-04-15 2021-04-14 Compositions and methods for treatment of neurological disorders

Publications (1)

Publication Number Publication Date
IL296857A true IL296857A (en) 2022-11-01

Family

ID=78081428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296857A IL296857A (en) 2020-04-15 2021-04-14 Preparations and methods for the treatment of neurological disorders

Country Status (9)

Country Link
US (2) US11753655B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135661A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023522883A (cg-RX-API-DMAC7.html)
KR (1) KR20230004617A (cg-RX-API-DMAC7.html)
CN (1) CN115715185A (cg-RX-API-DMAC7.html)
AU (1) AU2021255934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175406A1 (cg-RX-API-DMAC7.html)
IL (1) IL296857A (cg-RX-API-DMAC7.html)
WO (1) WO2021211700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296857A (en) * 2020-04-15 2022-11-01 Univ Texas Preparations and methods for the treatment of neurological disorders
WO2023102518A1 (en) * 2021-12-03 2023-06-08 The Board Of Regents Of The University Of Texas System Gnao1 gene therapy vectors and uses thereof
EP4713462A1 (en) * 2023-05-18 2026-03-25 Gencorrex Therapies Inc. Solute carrier family 6 member 8 vectors and methods for use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US9221890B2 (en) * 2011-10-25 2015-12-29 Indiana University Research And Technology Corporation Gigaxonin fusion protein and methods for treating giant axonal neuropathy
WO2015060722A1 (en) * 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
US10016514B2 (en) * 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
CA3045551A1 (en) * 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
IL280300B2 (en) * 2018-08-10 2025-06-01 Univ North Carolina Chapel Hill Optimized cln7 genes and expression cassettes and their use
IL296857A (en) * 2020-04-15 2022-11-01 Univ Texas Preparations and methods for the treatment of neurological disorders

Also Published As

Publication number Publication date
AU2021255934A1 (en) 2022-10-20
US20210324411A1 (en) 2021-10-21
WO2021211700A1 (en) 2021-10-21
US12534741B2 (en) 2026-01-27
KR20230004617A (ko) 2023-01-06
JP2023522883A (ja) 2023-06-01
CN115715185A (zh) 2023-02-24
US11753655B2 (en) 2023-09-12
EP4135661A4 (en) 2024-07-10
US20240102050A1 (en) 2024-03-28
EP4135661A1 (en) 2023-02-22
CA3175406A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US12454701B2 (en) Recombinant adeno-associated viral vector for gene delivery
US11338045B2 (en) Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
IL300263A (en) Plakophilin-2 (PKP2) gene therapy using an AAV vector
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
EP4055174A1 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
US20250262327A1 (en) Compositions and methods for treating dominant optic atrophy and x-linked retinoschisis
WO2022245919A1 (en) Methods and compositions for treating ocular diseases and disorders
IL297656A (en) Gene therapy with dual dysperlin vectors
EP4073087A1 (en) Recombinant adeno-associated viral vector for gene delivery
US20240342314A1 (en) Slc13a5 gene therapy vectors and uses thereof
WO2024220719A1 (en) Modified aav capsids for gene delivery
WO2023102406A1 (en) Vector genome design to express optimized cln7 transgene
AU2023211652A1 (en) Aav capsids for improved heart transduction and detargeting of liver
WO2023102518A1 (en) Gnao1 gene therapy vectors and uses thereof